GHENT, Belgium, July 8, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC.
The above legal entity informed that it has been granted discretionary power to vote for more than 3% of Ablynx' voting rights, as it shall exercise voting rights incorporated in 1,810,500 Ablynx shares, which represent 3.35% of the current 53,991,659 outstanding shares of Ablynx.
Such voting rights shall be exercised by FMR LLC, which controls the following companies acting as fund manager for various undertakings for collective investment, that hold a participation in Ablynx shares: Fidelity Management & Research Company, Pyramis Global Advisors LLC and Pyramis Global Advisors Trust Company.
Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has more than 30 programmes in the pipeline and seven Nanobodies in clinical development. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
Voor bijkomende informatie, gelieve contact op te nemen met
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Volg ons op Twitter @AblynxABLX
Ablynx media relaties Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
pdf format of the press release http://hugin.info/137912/R/1818479/629366.pdf